Grave’s Disease with Severe Hepatic Dysfunction: A Diagnostic and Therapeutic Challenge

Table 2

Follow-up investigations of the patient.

	At adm.	1st wk	2nd wk	3rd wk	At disch.	2nd month	5th month	6th month
TSH (mIU/L)	0.056		0.28	—			0.45	0.78
FT4 (ng/dL) (0.89–1.7)	3.45				2.1	1.9	1.69	1.24
T3 (nmol/L)	4.56				3.34	3.3	2.67	2.01
S. bilirubin (Total) (mg/dL)	15.8	10.5	8.4	5.5	4.5	4.14	3.5	3.12
Conjugated (mg/dL)	12.6	8.4	5.6	3.4	3.1	2.89	1.6	1.45
Unconjugated (mg/dL)	1.5	0.8	0.7	0.5	1.1	0.6	0.45	0.67
AST (U/L)	46	43	35	33	34	38	39	32
ALT (U/L)	43	44	37	32	36	40	36	34
Serum alkaline phosphatase (U/L)	364	252	198	168	155	133	101	98
S. Na^+ (mmol/L)	134	145	142	138	142	140	139	138
S. K^+ (mmol/L)	2.7	3.8	4.1	4.3	4.0	3.9	4.1	3.9